Damora Therapeutics, Inc. quarterly report, Q1 FY2022

Business Context and Reporting Period

Filing discrepancy: The request identifies Damora Therapeutics, Inc., but the supplied Form 10-Q is for Galecto, Inc. (Nasdaq: GLTO), a clinical-stage biotechnology company. This summary reflects the supplied Galecto filing.

The report covers the three months ended March 31, 2022, and compares results with the three months ended March 31, 2021. Galecto develops small-molecule therapies targeting galectin-3 and LOXL2 for fibrotic diseases and cancer. Its lead programs are GB0139, GB2064 and GB1211. The interim financial statements are unaudited and prepared under U.S. GAAP.

Financial and Operating Highlights

MetricQ1 2022Q1 2021Change
Product revenue$0$0No change
Research and development expense$13.2 million$10.0 millionUp 32.5%
General and administrative expense$3.7 million$3.6 millionUp 4.0%
Total operating expenses$16.9 million$13.6 millionUp 25.0%
Net loss$16.9 million$13.3 millionLoss increased $3.6 million
Net loss per share$0.67$0.53Loss per share increased
Cash used in operating activities$6.8 million$14.2 millionUse decreased $7.4 million

The company has no commercial products or product revenue and therefore does not report a meaningful gross margin or operating margin. Operating loss was $16.9 million in Q1 2022.

At March 31, 2022, cash and cash equivalents were $45.4 million, current marketable securities were $48.2 million, and noncurrent marketable securities were $8.2 million. Total cash, cash equivalents and marketable securities were approximately $101.8 million, compared with $109.2 million at December 31, 2021. Current assets were $97.0 million and current liabilities were $7.2 million. Total liabilities were $7.6 million, consisting primarily of accounts payable, accrued liabilities and operating lease liabilities; the filing does not report conventional debt.

Total assets were $108.9 million and stockholders’ equity was $101.3 million at March 31, 2022. Accumulated deficit was $173.1 million. The company had 25,261,832 common shares outstanding, unchanged from December 31, 2021.

Material Changes Versus the Prior Comparable Period

  • Research and development expense increased $3.2 million, primarily from higher clinical-trial spending for the GALACTIC-1 Phase 2b trial and the start of two Phase 2a trials. Personnel costs also increased, partly offset by lower manufacturing costs.
  • Research and development spending included $7.9 million for preclinical and clinical trial activities, up 71.0% year over year.
  • General and administrative expense increased $0.1 million to $3.7 million, with higher personnel costs offset by lower consulting costs.
  • Net loss increased 26.9% to $16.9 million, and diluted loss per share increased to $0.67 from $0.53.
  • Operating cash burn improved to $6.8 million from $14.2 million, partly reflecting working-capital changes, including a $6.5 million reduction in prepaid expenses and other current assets.
  • Investing cash use was $10.2 million, reflecting $26.4 million of marketable-security purchases, partly offset by $16.2 million of proceeds from sales. Investing cash use was $74.6 million in Q1 2021.
  • Stock-based compensation increased to $1.4 million from $1.0 million. The company granted 1,648,750 stock options during the quarter.
  • Unrealized losses on marketable securities and currency translation losses produced total other comprehensive loss of $0.4 million.

Guidance, Outlook, Risks and Unusual Items

Management expects continuing net losses and negative operating cash flows for the foreseeable future. Based on its current operating plan, management believes the approximately $101.8 million of cash, cash equivalents and marketable securities at March 31, 2022 will fund operating and capital requirements into the second half of 2024. This estimate depends on assumptions that may prove incorrect, and additional financing will be required thereafter or sooner if expenditures exceed expectations.

  • GB0139: The GALACTIC-1 Phase 2b IPF trial completed target enrollment of 141 patients in April 2022. Topline results were expected in mid-2023.
  • GB2064: The MYLOX-1 Phase 2a myelofibrosis trial was expected to complete enrollment in the second half of 2022, with interim results expected in mid-2022 and topline results in the first half of 2023.
  • GB1211: The GULLIVER-2 liver-cirrhosis trial completed enrollment in March 2022, with topline results expected in the fourth quarter of 2022. The company expected to initiate the GALLANT-1 NSCLC trial in the second quarter of 2022, with topline results expected in mid-2023.
  • The company had an effective shelf registration for up to $200 million of securities and an at-the-market program for up to $50 million of common stock. No ATM sales had occurred through March 31, 2022.
  • COVID-19 had delayed patient recruitment and increased costs, including for GALACTIC-1, and could further delay clinical trials, readouts and commercialization plans.
  • Key risks include clinical-trial failure or delay, regulatory nonapproval, safety or efficacy problems, manufacturing and supply constraints, dependence on third parties and key personnel, intellectual-property risks, competition and the need for additional capital.
  • The company reported no material legal proceedings, no material changes to previously disclosed risk factors and no material changes to commitments and contingencies.
  • Stock-based compensation and unrealized investment losses were notable noncash items. Unrecognized compensation expense related to unvested options was $14.9 million at March 31, 2022.

Important Facts for Investors to Verify

  • Confirm the issuer identity: the supplied filing is Galecto, Inc., not Damora Therapeutics, Inc.
  • Verify the company’s ability to meet the stated cash runway into the second half of 2024 against actual clinical-trial spending and enrollment progress.
  • Track results, timing and regulatory developments for GB0139, GB2064 and GB1211, including the effects of COVID-19-related delays.
  • Assess future financing needs, potential equity dilution and the availability or use of the ATM and shelf-registration facilities.
  • Review the company’s accumulated deficit, continuing lack of product revenue and reliance on successful clinical development for eventual commercialization.
  • Evaluate the liquidity and credit risk of the corporate bonds and other marketable securities held by the company.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.